Barclays analyst Luke Sergott upgraded Charles River (CRL) to Overweight from Equal Weight with a price target of $195, up from $165. The firm cites stabilized drug discovery demand and valuation for the upgrade. Charles River offers upside to earnings estimates and valuation as the demand environment should get incrementally better from here, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRL:
- Charles River Labs: Navigating Leadership Changes and Market Challenges with a Hold Rating
- Hold Rating on Charles River Labs Amid Leadership Transition and Market Uncertainty
- Trump announces $15B libel suit against New York Times: Morning Buzz
- Trump announces $15 libel suit against New York Times: Morning Buzz
- Charles River Labs CFO Resignation and Interim Appointment